BYSI
BeyondSpring Inc.
$1.71
0.00%
$70.3M
No data for this timeframe.
Vol
Market Cap$70.3M
Cap SizeMicro Cap
SEC Reports3
Press Releases3
Recent Activity
Jun 4, 2026
SEC
BeyondSpring announced a leadership transition effective July 1, 2026: founder/CEO Dr. Lan Huang steps down as CEO (rema
8-K — Impact 4/10
Jun 4, 2026
other
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
<p>FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tr
Jun 2, 2026
Press
BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab + Plinabulin + doceta
Impact 7/10
May 13, 2026
SEC
BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.4M, improved from a
PRESS-RELEASE — Impact 4/10
May 13, 2026
SEC
BeyondSpring reported Q1 2026 financial results with a net loss from continuing operations of $2.4M, slightly improved f
8-K — Impact 4/10
Apr 1, 2026
Insider
Fabbio Patrick sold 22,165 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Majeti Jiangwen sold 21,730 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Delaney Brendan sold 20,427 shares
Director @ $0.00 ($0.00)
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 2, 2023 | Baird | MAINTAIN | Outperform |
| Dec 2, 2021 | Jefferies | DOWNGRADE | Buy → Hold |
| Dec 2, 2021 | B of A Securities | DOWNGRADE | Buy → Underperform |
| Dec 1, 2021 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Sep 20, 2021 | HC Wainwright & Co. | MAINTAIN | Buy |
Latest Reports
NEUTRAL
8-K
4/10
BeyondSpring announced a leadership transition effective July 1, 2026: founder/CEO Dr. Lan Huang steps down as CEO (rema
Jun 4, 2026
BULLISH
Press
7/10
BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab + Plinabulin + doceta
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
4/10
BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.4M, improved from a
May 13, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Fabbio Patrick | A | $0.00 |
| Apr 1, 2026 | Majeti Jiangwen | A | $0.00 |
| Apr 1, 2026 | Delaney Brendan | A | $0.00 |
| Apr 1, 2026 | Lu Yingjuan | A | $0.00 |
| Apr 1, 2026 | Huang Lan | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Fabbio Patrick | Director | A | 22,165 | $0.00 | $0.00 |
| Apr 1, 2026 | Majeti Jiangwen | Director | A | 21,730 | $0.00 | $0.00 |
| Apr 1, 2026 | Delaney Brendan | Director | A | 20,427 | $0.00 | $0.00 |
| Apr 1, 2026 | Lu Yingjuan June | Chief Scientific Officer | A | 17,840 | $0.00 | $0.00 |
| Apr 1, 2026 | Huang Lan | Chief Executive Officer | A | 11,514 | $0.00 | $0.00 |
| Apr 1, 2026 | Xu Sihai | Director | A | 18,689 | $0.00 | $0.00 |
| Apr 1, 2026 | Kirkby Matthew | Director | A | 23,902 | $0.00 | $0.00 |
| Mar 20, 2026 | Huang Lan | Chief Executive Officer | G | 260,582 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
4/10
BeyondSpring announced a leadership transition effective July 1, 2026: founder/CEO Dr. Lan Huang ste
Jun 4, 2026
NEUTRAL
PRESS-RELEASE
4/10
BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.
May 13, 2026
NEUTRAL
8-K
4/10
BeyondSpring reported Q1 2026 financial results with a net loss from continuing operations of $2.4M,
May 13, 2026
BULLISH
7/10
BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab +
Jun 2, 2026
NEUTRAL
3/10
BeyondSpring filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, which
Mar 25, 2026
BULLISH
8/10
BeyondSpring reported its 2025 financial results and highlighted significant clinical progress for i
Mar 25, 2026
Historical analyst distribution (last covering-analyst action May 2023): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
9 analyst firms have rated this stock: 1 upgrades, 4 downgrades, 7 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 2, 2023 | Baird | MAINTAIN | — | Outperform |
| Dec 2, 2021 | Jefferies | DOWNGRADE | Buy | Hold |
| Dec 2, 2021 | B of A Securities | DOWNGRADE | Buy | Underperform |
| Dec 1, 2021 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Sep 20, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Sep 9, 2021 | Baird | INITIATE | — | Outperform |
| Aug 4, 2021 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Apr 5, 2021 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jan 11, 2021 | B of A Securities | INITIATE | — | Buy |
| Dec 29, 2020 | Evercore ISI Group | INITIATE | — | Outperform |
| Jun 15, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 30, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Feb 7, 2020 | Jefferies | INITIATE | — | Buy |
| Jan 10, 2020 | Nomura | INITIATE | — | Buy |
| Dec 3, 2019 | William Blair | INITIATE | — | Outperform |
| Jun 22, 2018 | Maxim Group | MAINTAIN | Buy | Buy |
| Apr 4, 2017 | Rodman & Renshaw | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2024 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
<p>FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=HdOPqc6qGF657H_xCswkWUvhc7-LiFYdrQPRIm-
Jun 2, 2026
fda
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
<p>FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=5yYcgnHBvdDUhY5749UrWzluJorRLMFwbspI2ER
May 20, 2026
Clinical Trial
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Phase Phase 3 — COMPLETED
May 18, 2026
routine
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
<p>FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YBLO9IImpZ8ukz1fczCHs2ILQUrUfI7M-eJ3fgsq
May 13, 2026
earnings
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
<p align="center">AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to I
May 13, 2026
earnings_calendar
BYSI Q1 2026 Earnings Scheduled — 2026-05-13
Apr 22, 2026
other
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
<p align="center">New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with L
Mar 30, 2026
routine
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
<p>FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=X4CHv9Oa_maj-DCDwv0rHZdMcJEW59_3TYFvfh
Mar 27, 2026
earnings_calendar
BYSI Q4 2025 Earnings After Market Close — 2026-03-27
Mar 25, 2026
regulatory
BeyondSpring Files 2025 Annual Report on Form 10-K
<p align="left">FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=t8evjSMrL1DALCGfvgqmtMKoO
Mar 25, 2026
earnings
BeyondSpring Reports 2025 Year-End Financial Results
<p><strong>Plinabulin (BeyondSpring's Lead Program):</strong></p>